Abstract
Melphalan can rarely cause interstitial pneumonitis and fibrosis. Although it has been reported previously in patients after conventional doses, we report four cases developing diffuse interstitial pneumonitis (DIP) after high-dose melphalan-based therapy. In a 3-year period, four of 57 (7%) consecutive patients undergoing high-dose melphalan (200 mg/m2; MEL 200) were identified with DIP. Two patients who were heavily pre-treated with alkylators developed progressive respiratory failure despite high-dose steroids and eventually died. The other two patients previously treated with vincristine, adriamycin, and dexamethasone (VAD) improved dramatically on high-dose steroids with complete resolution of their pneumonitis. Melphalan should be added to the growing list of alkylators causing pulmonary toxicity. Bone Marrow Transplantation (2000) 26, 1107–1109.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Calabresi P, Parks R . Alkylating agents, antimetabolites, hormones, and other antiproliferative agents. In: Goodman LS, Gilman A (eds) Pharmacologic Basis of Therapeutics Macmillan: Toronto 1975 1348–1359
Gillett DG, Ford GT . Drug-induced lung disease. In: Thurlbeck W (ed) The Lung Structure, Function and Disease Williams and Wilkins: Baltimore 1978 21–42
Codling BW, Chakera TMH . Pulmonary fibrosis following therapy with melphalan for multiple myeloma J Clin Pathol 1972 25: 668–573
Taetle R, Dickman P, Feldman P . Pulmonary histopathologic changes associated with melphalan therapy Cancer 1978 42: 1239–1245
Westerfield BT, Michalski JP, McCombs C, Light RW . Reversible melphalan-induced lung damage Am J Med 1980 68: 767–771
Jones RB, Mathes S, Shpall EJ et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine J Natl Cancer Inst 1993 85: 640–647
Chan CK, Hyland RH, Hutcheon MA . Pulmonary complications following bone marrow transplantation Clin Chest Med 1990 11: 323–332
Durant JR, Norgard MJ, Murad TM et al. Pulmonary toxicity associated with bischloroethylnitrosurea (BCNU) Ann Intern Med 1979 90: 191–194
Rosenow EC III, Myers JL, Swensen SJ, Pisani RJ . Drug-induced pulmonary disease. An update Chest 1992 102: 239–250
Malik S, Jeffrey L, Myers J et al. Lung toxicity associated with cyclophosphamide use two distinct patterns Am J Respir Crit Care Med 1996 154: 1851–1856
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Akasheh, M., Freytes, C. & Vesole, D. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 26, 1107–1109 (2000). https://doi.org/10.1038/sj.bmt.1702664
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702664
Keywords
This article is cited by
-
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas
Annals of Hematology (2021)
-
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike
Bone Marrow Transplantation (2012)
-
Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita
Bone Marrow Transplantation (2011)